Switching properties of fluorescent photochromic poly(methyl methacrylate) with spironaphthoxazine and D-π-A type pyran-based fluorescent dye.
Fluorescent photochromic poly(methyl methacrylate) (PMMA) with spironaphthoxazine (SPO) and D-π-A type pyran-base fluorescent dye as a fluorophore was synthesized by typical free radical copolymerization. The poly(MMA-co-SPO-co-fluorophore) in both solution and solid film exhibited excellent photoregulated fluorescence switching behavior and reversible modulation of fluorescence intensity using alternating irradiation with UV and visible light. The poly(MMA-co-SPO-co-fluorophore) also showed viscosity and conductivity switching behaviors along with photoresponse.
Synthesis of chemical and electrochemical 'off-on-off' fluorescent switches of new 5H-benzo(b)carbazole-6, 11-dione derivatives
Synthesis of a new series of compounds belonging to the 5H-benzo(b)carbazole-6,11- dione family was accomplished employing a nucleophilic amino addition reaction followed by the Suzuki coupling reaction. The structures of the synthesized compounds were confirmed by FT-IR, 1 H NMR, 13 C NMR and Mass spectral analysis. The synthesized compounds were proved to be good molecular switches exhibiting chemical and electrochemical fluorescent switching prop- erties by UV-vis, photoluminescence (PL), and cyclic voltagram (CV) studies. a 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
Multiple-dose pharmacokinetics of moxisylyte after oral administration to healthy volunteers.
The pharmacokinetics of moxisylyte in plasma and urine was investigated after oral administration. Twelve subjects were treated orally, twice daily with 240 mg of the drug for 6 days; on day 7, the subjects received a last dose of 240 mg of moxisylyte. Moxisylyte was assayed in plasma and urine by a specific HPLC method with fluorimetric detection. Moxisylyte was absorbed rapidly and changed to its metabolites immediately after drug administration; unchanged moxisylyte was not found in plasma. Two metabolites were found in plasma and urine: conjugated desacetylmoxisylyte (DAM) and the conjugate of desmethylated DAM (MDAM). The pharmacokinetic parameters determined after the first oral administration were not modified on multiple dosing. The apparent elimination half-lives of conjugated DAM and MDAM were 2.3 and 3.5 h, respectively. Elimination of these two metabolites in urine averaged 50 and 10%, respectively.